Multiple target antigen stimulating cell therapy - HengRui YuanZheng Biotechnology

Drug Profile

Multiple target antigen stimulating cell therapy - HengRui YuanZheng Biotechnology

Alternative Names: Cytotoxic T-cell therapy - HengRui YuanZheng; Dendritic cell therapy - HengRui YuanZheng; MASCT I; MASCT-1; Neo-MASCT

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HengRui YuanZheng Bio-Technology
  • Class Antineoplastics; Cell therapies; Dendritic cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 31 Oct 2017 Shenzhen Second People's Hospital plans a clinical trial for Colorectal cancer (Late-stage disease, Second-line therapy or greater) in China in December 2017 (ChiCTR-ONC-17013136)
  • 06 Jul 2017 HengRui YuanZheng Bio-Technology plans a phase I/II trial for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in China (NCT03205930)
  • 25 Jan 2017 HengRui YuanZheng Bio-Technology plans a phase I trial for Cancer presumably in China (NCT03034304)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top